Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options—An Analysis From the Global Germ Cell Cancer Group
Authors:
- Darren R. FeldmanDFDarren R. Feldman
- Anja LorchALAnja Lorch
- Andrew KramarAKAndrew Kramar
- Costantine AlbanyCACostantine Albany
- Lawrence H. EinhornLELawrence H. Einhorn
- Patrizia GiannatempoPGPatrizia Giannatempo
- Andrea NecchiAndrea Necchi
- Aude FlechonAFAude Flechon
- Helen BoyleHBHelen Boyle
- Peter ChungPCPeter Chung
- Robert A. HuddartRHRobert A. Huddart
- Carsten BokemeyerCBCarsten Bokemeyer
- 1 February 2016
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (4) , 345-351
Abstract
Purpose: To define characteristics, treatment response, and outcomes of men with brain metastases (BM) from germ cell tumors (GCT). Patients and Methods: Data from 523 men with BM from GCT were collected retrospectively from 46 centers in 13 countries by using standardized questionnaires. Clinical features were correlated with overall survival (OS) as the primary end point. Results: BM were present at initial diagnosis in 228 men (group A) and at relapse in 295 men (group B). OS at 3 years (3-year OS) was superior in group A versus group B (48% v 27%; P < .001). Multiple BM and the presence of liver or bone metastasis were independent adverse prognostic factors in both groups; primary mediastinal nonseminoma (group A) and elevations of α-fetoprotein of 100 ng/mL or greater or of human chorionic gonadotropin of 5,000 U/L or greater (group B) were additional independent adverse prognostic factors. Depending on these factors, the 3-year OS ranged from 0% to 70% in group A and from 6% to 52% in group B. In group A, 99% of patients received chemotherapy; multimodality treatment or high-dose chemotherapy was not associated with statistically improved survival in multivariable analysis. In group B, only 54% of patients received chemotherapy; multimodality treatment was associated with improved survival compared with single-modality therapy (hazard ratio, 0.51; 95% CI, 0.36 to 0.73; P < .001), as was high-dose compared with conventional-dose chemotherapy (hazard ratio, 0.41; 95% CI, 0.24 to 0.70; P = .001). Conclusion: Men with BM from GCT have poor OS, particularly if additional risk factors are present. High-dose chemotherapy and multimodality treatment seemed to improve survival probabilities in men with BM at relapse.Keywords
This publication has 13 references indexed in Scilit:
- Synchronous versus metachronous brain metastasis from testicular germ cell tumors (TGCT): an analysis from the Spanish Germ Cell Cancer Group data baseClinical and Translational Oncology, 2014
- Brain metastases associated with germ cell tumors may be treated with chemotherapy aloneCancer, 2014
- Management of Brain Metastases from Germ Cell Tumors: A Single Center ExperienceOncology, 2013
- Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancerAnnals of Oncology, 2012
- Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line ChemotherapyJournal of Clinical Oncology, 2010
- Brain metastases from testicular germ cell tumors: A retrospective analysisInternational Journal of Urology, 2009
- Brain metastasis from non-seminomatous germ cell tumor of the testisExpert Review of Anticancer Therapy, 2007
- Malignant Germ Cell Tumors Metastatic to the Brain: A Model for a Curable Neoplasm? The Freiburg Experience and a Review of the LiteratureJournal of Neuro-Oncology, 2002
- The management of brain metastasis in nonseminomatous germ cell tumoursBJU International, 1999
- Treatment of brain metastases in patients with testicular cancer.Journal of Clinical Oncology, 1997